Abstract HCC1/CAPERα is considered to be a novel human tumor-associated antigen, and the tumor-specific immunity of
Introduction
Cancer has long been recognized as a highly complex disorder that involves not only the interplay of genomic changes but also factors including the immunological, hormonal, environmental, and other disease [1] . There is persuasive evidence that the immune system of the cancer patients have the capability of sensing abnormalities in structure, function, intracellular location, and other alterations of cellular participants in carcinogenesis. Previous studies have demonstrated that cancer sera contain antibodies that react with a unique group of autologous cellular antigens called tumor-associated antigens (TAAs) [2, 3] . These antigens are probably cellular proteins, such as p53, p62, p90, and p16, whose aberrant regulation or overexpression is capable of leading to tumorigenesis [4] [5] [6] [7] [8] . Therefore, these cancer-associated anti-TAA antibodies may be regarded as reporters, which can identify aberrant cellular factors involved in the transformation process in cancer [9] .
HCC1, a splicing factor that is highly homologous to U2AF65 (splicing factor U2AF 65 kDa subunit), was originally isolated as an autoantigen from a patient with liver cirrhosis who later progressed to hepatocellular carcinoma [10, 11] . It was also known as CAPERα, a protein for transcriptional coactivator of activating protein-1 and estrogen receptors [12] . As a novel nuclear protein, HCC1/CAPERα contains RNA-binding domains and a long region rich in arginine and serine, was previously identified as RNA binding motif protein 39 (RBM39), which might contribute to alternative splicing, an important mechanism to produce mRNA, protein, and functional diversity by modulation of processing of pre-mRNA [13] . HCC1/CAPERα has also been reported to have an important role in modulating the oncogenic activity of Rel/NF-κB [14] . HCC1/CAPERα comprises two alternatively spliced isoforms termed HCC1.3 and HCC1.4. The fulllength cDNA clones encoded 530 amino acids termed HCC1.4 and 18-nucleotide (six-amino acid) deletion was another representative clone, named as HCC1.3 [15] . In our recent study, we found that HCC1.4 and HCC1.3 as TAAs had different autoantibody immune responses (data not published yet); however, whether HCC1.4 and HCC1.3 had different function as reporters identifying aberrant cellular mechanisms in tumorigenesis was not sure yet.
Lung cancer has become the most common malignant tumor and the major cause of cancer deaths worldwide [16] . Non-small cell lung cancer (NSCLC) accounts for more than 85 % of all lung cancers when compared with adenocarcinomas, squamous cell, and large cell carcinomas. Approximately 75 % of patients with NSCLC present with advanced stage is un-resectable or metastatic [17] . HCC1/CAPERα has been described to be overexpressed in NSCLC and other cancers [18, 19] . In the current study, we aimed to investigate the roles of HCC1.4 and HCC1.3 in NSCLC cells growth and migration.
Materials and methods

Cell lines and cell extracts
Six different tumor cell lines (lung cancer (H460, H1299), hepatocellular carcinomar (HepG2, SUN449), breast cancer (SKBR3), gastric cancer (AGS)) were obtained from the tumor cell bank of our laboratory and cultured following the specific protocol for each cell line. Cells grown in monolayers were solubilized in sample buffer containing protease inhibitors after sonication. Solubilized lysates were briefly denatured before electrophoresis on sodium dodecyl sulfatepolyacrylamide gels. H1299 cells were transfected with pcDNA3.1-HCC1.3, pcDNA3.1-HCC1.4, and pcDNA3.1 vectors respectively, using Lipofectamine™ LTX (Invitrogen, Carlsbad, CA) according to manufacturer's protocol. The stable cell lines H1299-HCC1.3, H1299-HCC1.4, and their counterparts, H1299-pcDNA3.1 were established following selection with 1 mg/ml G418 and maintained with 0.5 mg/ml G418. The stable expression of HCC1.3 and HCC1.4 proteins were confirmed by Western blot as described below.
Western blotting and indirect immunofluorescence (IIF) assay
Western blotting was performed by using our previously described method [20] . Antibody against HCC1/CAPERα was purchased from Abcam (Cambridge, MA), antibody against β-actin from Santa Cruz (Santa Cruz, CA). Immunoreactive protein bands were visualized by the ECL kit (Amersham, Arlington Heights, IL) according to the manufacturer's instructions.
IIF assay was performed by using a previously described method [21] . In brief, after transfected with pcDNA3.1-HCC1.3, pcDNA3.1-HCC1.4, and pcDNA3.1vector, respectively, H1299 cells cultured in an eight-well chamber culture slide (BD-Falcon, Bedford, MA) were fixed with 100 % precold methanol for 5 min at −20°C, and then permeabilized in 100 % pre-cold acetone for 3 min at −20°C. Cell samples were incubated with polyclonal HCC1/CAPERα antibody with 1:40 for 1 h at room temperature, followed by incubation with antihuman IgG FITC conjugated secondary antibody (Invitrogen, Carlsbad, CA) for 1 h at room temperature at a 1:200 dilution. Confocal fluorescence images were acquired with a laser scanning microscope (LSM 700, Zeiss, New York, NY), using a×20 objective and processed with ZEN 2009 software (Zeiss, CA).
Cell proliferation assay
Cells proliferation was detected using MTT (Promega, Madison, WI). Briefly, H1299 cells were harvested, counted, and seeded into 96-well microliter plates (Thermo Scientific, Waltham, MA) at a density of 5×10 3 cell/ml (200 μl cell suspensions) and incubated for 24, 48, and 72 h, respectively. After indicated time points, the cell proliferation was determined by the MTT assay as described according to the manufacturer's instructions.
Cell migration assay
Wound healing assay was performed as described previously [22] . Transwell assay were performed using 24-well permeable supports with 8-μm pore (Corning, NY). After 24 h incubation, cells that had migrated into the lower surface of the filter were stained with 0.05 % crystal violet or fluorescent dye Calcein AM (Corning) according to the manufacturer's instructions. The fluorescence was read by fluoroskan ascent microplate fluorometer (Thermo Scientific).
Immunohistochemistry (IHC) with tissue microarray (TMA) NSCLC TMA slides with normal tissue control (LC10012, 50 cases/100 cores, including clinical stages and pathology grades) were purchased (US Biomax, Inc., Rockville, MD) and used to detect the expression of the HCC1/CAPERα. IHC assay was performed according to previously described methods [21, 23] . The slides were then observed under light microscopy. All IHC results were read blindly by two independent researchers. A four-level scoring system (−, negative; +, low expression level; ++, moderate expression level; +++, high expression level) was used to evaluate the staining intensity.
Statistics
All data are represented as means±standard deviation (SD). Statistical analysis was performed using an unpaired twotailed t test or χ 2 test in SPSS13.0. Two significant levels (P<0.05 or P<0.01) were used.
Results
Expression of HCC1/CAPERα in different cancer cell lines
The expression of HCC1/CAPERα in six cancer cell lines was analyzed by Western blotting. As shown in Fig. 1a , based on the expression level of internal control β-actin, cancer cell lines such as HepG2, SUN449, and SKBR3 exhibited a strong reactivity to anti-HCC1/CAPERα. H460, H1299, and AGS cell lines exhibited weak reactivity.
Differential expression of HCC1.3 and HCC1.4 d in NSCLC cells
The stable HCC1.3 and HCC1.4 overexpression cell lines were distinguished, and their protein expression was confirmed by Western blotting and the intracellular localization by indirect immunofluorescence assay (Fig. 1b-c) . As shown in Fig. 1b, the As shown in Fig. 3b , after 24 h incubation with cell cultures, cells that overexpressed HCC1.4 nearly formed 100 % confluent monolayer, while the free surface area of the scratch was still observed for H1299-vector and H1299-HCC1.3 cells in wound healing assay. The transwell assay revealed the different migration capacity of H1299 transfectants (Fig. 3a, c) . The H1299-HCC1.4 cells had the significantly higher level of migration activity compared with H1299-vector cells (Fig. 3c) . Similar results can also be observed when transfected cells were stained with crystal violet (Fig. 3a) .
HCC1/CAPERα is over-expressed in NSCLC tissues
The express of HCC1/CAPERα in NSCLC tissues and adjacent normal lung tissues was examined by immunohistochemistry with TMA slides. The TMA slide containing 45 cases of carcinoma, 45 cases of adjacent tissue, and five normal tissue specimens were commercially available for this study. As shown in Table 1 , 43 of 45 (95.6 %) NSCLC tissues were stained positive with monoclonal anti-HCC1/CAPERα antibody, and 18 of the 50 (36 %) adjacent and normal lung tissues were positively stained. The frequency of HCC1/CAPERα expression in lung cancer tissues was significantly higher than that in adjacent and normal lung tissues (P<0.01). gender, and age due to the limited number of tissue specimens in this study.
Discussion
Identification of the intracellular antigens that involved in the immune response of cancer patients can provide vital information regarding the molecular mechanisms participating in the malignant transformation process. The possible mechanisms underlying the production of the autoantibodies may be related to the alteration of molecular structure or location of autoantigens [24, 25] . Splicing, the removal of introns from mRNA precursors, is an essential step in eukaryotic gene expression [26] . HCC1/CAPERα, as a splicing factor, regulates both steroid hormone receptor-mediated transcription and alternative splicing, which are functionally coupled to modulate gene expression [13] . In our previous study, we have also found that HCC1/CAPERα can induce immune responses in lung cancer patients (data not published yet). The six-amino acid deletion in HCC1.3 was located in the third RNA recognition motif (RRM) domain [12, 15] . The RRMs consisted of ribonucleoprotein consensus sequence (RNP-CS), which had been shown to be responsible for both RNA and single-stranded DNA binding specificity [27] [28] [29] [30] , and mediate protein-protein interaction [31] [32] [33] . In another study from our lab, both HCC1.3 and HCC1.4 have been demonstrated as tumor-associated antigens which can induce humoral immune responses in hepatocellular carcinoma patients (data were not published yet). The study has also shown that the deletion of amino acid of intracellular antigen may reduce its affinity for the autoimmune immune response to cellular components. The fact that the deletion of six-amino acid in HCC1.3 results in the loss of the RNP-like motif in the third RNP-CS domain may have some functional consequences, suggesting that HCC1.3 and HCC1.4 were indistinguishable in their binding and transcriptional coactivation properties [12] . HCC1/CAPERα can also interact with both subunits of U2AF heterodimer and accumulate distinct complexes of splicing factors within the nucleus [34] , but the function of HCC1/CAPERα in tumorigenesis has not previous reported yet.
In the present study, we have examined the HCC1/CAPERα protein level in NSCLC by immunohistochemistry. As expected, low levels of HCC1/CAPERα protein were observed in adjacent and normal lung tissues which showed negative staining for anti-HCC1/CAPERα (Fig. 4a-b ) compared with a prostate adenocarcinoma specimen (Fig. 4c ) and lung cancer tissues (Fig. 4d-f) . Moreover, the staining occurred in both the cytoplasm and nuclei of these cells. Collectively, our results showed that HCC1/CAPERα have significant higher immunogenicity in NSCLC tissues compared with adjacent and normal tissues (P<0.01), suggesting that HCC1/CAPERα may play an important role in human lung carcinogenesis.
To further investigate the function of HCC1.3 and HCC1.4 in lung cancer tumorigenesis, NSCLC H1299 cells were transfected to demonstrate the overexpression of HCC1.3 or HCC1.4 in vitro. Since poly-or monoclonal antibody against HCC1.3 was not commercially available, we used polyclonal antibody against HCC1/CAPERα to detect the expression of HCC1.3 or HCC1.4 in Western blot and immunofluorescence assay. It was found that HCC1/CAPERα mainly expressed in the nucleus of H1299 cells, also expressed in the peri-nuclear region or cytoplasm of dividing cells. It is of great importance to explore the localization of proteins at the subcellular level, as it leads to a better understanding of protein function, interaction networks, and cellular signaling pathways [35] . This special localization might be correlated to the function of HCC1/CAPERα protein as a splicing factor. Our finding indicated the novel distribution of HCC1/CAPERα protein, which might contribute to its roles and function in lung cancer tumorigenesis. We also showed that overexpression of HCC1.4 significantly increased the proliferation of H1299 cells compared with HCC1.3 and empty vector. Therefore, it may suggest that HCC1.4, the full length of CAPERα, not HCC1.3, play an important role in lung cancer cell proliferation. Moreover, when the trans-membraned cells in transwell assay were stained with crystal violet, similar results can be observed. The data indicated that cells overexpressing HCC1.4 showed the highest level of migratory ability compared with cells transfected with either empty vector or HCC1.3. The results may provide new evidence that HCC1.3 and HCC1.4 have differential expression in lung cancer cells and their distinct roles in regulation of tumor cell biology. It is consistent with that SR-related proteins may not only be involved in pre-mRNA processing but have a more complex array of functions in mammalian cells [36] .
In summary, the present findings in this study indicate that the full length of HCC1.4, or CAPERα may play an important role in lung cancer tumorigenesis. These data provide further information to explain why HCC1.3 and HCC1.4 can induce different autoimmune responses in patients with cancers. This preliminary study also suggests that HCC1.4/CAPERα may be a potential diagnostic target for lung cancer.
